Original Research
Published on 23 Jun 2025
Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma
in Cancer Immunity and Immunotherapy
- 198 views